These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 23675934)
21. Quantum-Mechanics Methodologies in Drug Discovery: Applications of Docking and Scoring in Lead Optimization. Crespo A; Rodriguez-Granillo A; Lim VT Curr Top Med Chem; 2017; 17(23):2663-2680. PubMed ID: 28685695 [TBL] [Abstract][Full Text] [Related]
22. The role of early in vivo toxicity testing in drug discovery toxicology. Fielden MR; Kolaja KL Expert Opin Drug Saf; 2008 Mar; 7(2):107-10. PubMed ID: 18324874 [TBL] [Abstract][Full Text] [Related]
23. Identification of chemically diverse GABA Mehta P; Srivastava S; Sharma M; Singh I; Malik R Int J Biol Macromol; 2018 Nov; 119():1113-1128. PubMed ID: 30098361 [TBL] [Abstract][Full Text] [Related]
24. Quantum mechanics in structure-based drug design. Peters MB; Raha K; Merz KM Curr Opin Drug Discov Devel; 2006 May; 9(3):370-9. PubMed ID: 16729734 [TBL] [Abstract][Full Text] [Related]
26. Toxicology testing in drug discovery and development. Dorato MA; Buckley LA Curr Protoc Toxicol; 2007 Feb; Chapter 19():Unit19.1. PubMed ID: 23045141 [TBL] [Abstract][Full Text] [Related]
27. Clinical pharmacokinetic registration file for NDA and ANDA procedures. Marzo A Pharmacol Res; 1997 Dec; 36(6):425-50. PubMed ID: 9446710 [TBL] [Abstract][Full Text] [Related]
28. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102 [TBL] [Abstract][Full Text] [Related]
29. De-risking drug discovery with ADDME -- avoiding drug development mistakes early. Tsaioun K; Jacewicz M Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206 [TBL] [Abstract][Full Text] [Related]
30. Regulatory considerations for preclinical development of anticancer drugs. DeGeorge JJ; Ahn CH; Andrews PA; Brower ME; Giorgio DW; Goheer MA; Lee-Ham DY; McGuinn WD; Schmidt W; Sun CJ; Tripathi SC Cancer Chemother Pharmacol; 1998; 41(3):173-85. PubMed ID: 9443633 [TBL] [Abstract][Full Text] [Related]
32. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Masimirembwa CM; Bredberg U; Andersson TB Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837 [TBL] [Abstract][Full Text] [Related]
33. ADME and toxicity in early drug discovery. Zhong HA Curr Top Med Chem; 2013; 13(11):1255-6. PubMed ID: 23675933 [No Abstract] [Full Text] [Related]
34. Overview of drug discovery and development. Ator MA; Mallamo JP; Williams M Curr Protoc Pharmacol; 2006 Dec; Chapter 9():Unit9.9. PubMed ID: 22294181 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors. Ren HC; Sai Y; Chen T Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):121-132. PubMed ID: 30039459 [TBL] [Abstract][Full Text] [Related]
36. Pharmacophore modeling for ADME. Guner OF; Bowen JP Curr Top Med Chem; 2013; 13(11):1327-42. PubMed ID: 23675939 [TBL] [Abstract][Full Text] [Related]
37. Virtual Screening of Novel Glucosamine-6-Phosphate Synthase Inhibitors. Lather A; Sharma S; Khatkar A Comb Chem High Throughput Screen; 2018; 21(3):182-193. PubMed ID: 29600755 [TBL] [Abstract][Full Text] [Related]
38. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective. Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536 [TBL] [Abstract][Full Text] [Related]